Lexeo Therapeutics, Inc. Common Stock (LXEO) Investor Relations Documents

Lexeo Therapeutics, Inc. Common Stock (LXEO) investor relations documents from the company's IR site: 8 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2023-08-28	Press release	LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovasc
2023-08-01	Press release	LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogeni
2023-06-13	Press release	LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical
2023-05-02	Press release	LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual
2023-05-02	Press release	LEXEO - Press Release (ASGCT Announcement )_vFinal Download PDF • 116.32 KB
2022-05-03	Press release	LEXEO - Press Release (ASGCT Announcement) FINAL Download PDF • 181.63 KB
2022-03-21	Press release	Lexeo - March Investor Conferences PR vF Download PDF • 148.20 KB
2021-04-28	Press release	LEXEO Announces Upcoming Data Presentations Download PDF • 63.00 KB

LXEO overview · LXEO earnings · LXEO financials · LXEO KPIs · LXEO ownership · LXEO peers · LXEO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.